Loading...
•
Mar 31, 2024
4DMT Q1 2024 Earnings Report
4D Molecular Therapeutics reported first quarter 2024 financial results and provided operational highlights.
Key Takeaways
4DMT reported a net loss of $32.4 million for Q1 2024, compared to a net loss of $28.7 million for Q1 2023. Cash, cash equivalents, and marketable securities were $589 million as of March 31, 2024, expected to fund operations into H1 2027.
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, enabling advancement into Phase 3 expected by Q1 2025.
Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at ASRS in July 2024.
Interim clinical data from Phase 1/2 AEROW clinical trial expected to be presented at the European Cystic Fibrosis Society Conference in June 2024.
Completed upsized public follow-on offering with total gross proceeds of $337 million, resulting in $589 million in cash and equivalents as of March 31, 2024.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4DMT anticipates several milestones across its product pipeline.
Positive Outlook
- Initial interim 24-week landmark analysis of Phase 2 PRISM Population Extension cohort expected at ASRS Annual Scientific Meeting on July 17-20, 2024.
- Update on Phase 3 clinical trial design for 4D-150 expected in Q3 2024.
- First Phase 3 clinical trial initiation for 4D-150 expected in Q1 2025.
- IND filing for 4D-175 expected in Q2 2024.
- Phase 1 initiation for 4D-175 expected in H2 2024.
Challenges Ahead
- No specific negative guidance mentioned in the provided text.